Corporate Profile
Taxus Cardium Pharmaceuticals is an advanced regenerative therapeutics company that is focused on the late-stage clinical and commercial development of regenerative medicine therapeutics including Generx®, an interventional cardiology, angiogenic gene therapy product candidate designed for the treatment of Cardiac Microvascular Insufficiency due to advancing coronary artery disease, and Excellagen®, an FDA-cleared acellular biological skin substitute designed as a professional-use advanced wound care product for the treatment of chronic non-healing diabetic foot, venous and pressure ulcers, which also has multiple additional potential tissue regeneration applications based on stem cells and other biologics.
Stock Quote
CRXM (Common)
ExchangeOTC BB (US Dollar)
Price$0.55
Change (%) Stock is Up 0.02 (3.77%)
Volume10,768
Data as of 07/25/14 3:46 p.m. ET
Minimum 20 minute delay
Refresh quote
Stock Chart
Stock chart for: 03NA000000CRXM
Recent News
DateTitle 
06/24/14Cardium Announces Positive Interim Phase 3 Clinical Data Showing Significant Efficacy of Generx® Angiogenic Gene Therapy for Myocardial Ischemia Due to Coronary Artery Disease at the 2014 BIO International ConventionPrinter Friendly Version
06/12/14Cardium To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The 2014 BIO International ConventionPrinter Friendly Version
05/22/14Taxus Cardium To Present On Advanced Regenerative Therapeutics Development Activities At Marcum Microcap ConferencePrinter Friendly Version
05/12/14Taxus Cardium’s Excellagen® Selected For Use With Stem Cells In Eu-Funded Human Clinical StudyPrinter Friendly Version
Primary IR Contact
Shareholder Services
Corporate Communications/Investor Relations
11750 Sorrento Valley Road
San Diego, CA 92121

Phone: 858-436-1018
E-mail: investorrelations@cardiumthx.com


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.